# OnCo record neladalkib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/neladalkib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "neladalkib" ;
  schema:name "Neladalkib"@en ;
  schema:description "A fourth-generation ALK pill that works after lorlatinib and avoids the TRK-related brain side effects; under FDA priority review with a decision due 27 November 2026."@en ;
  schema:url <https://onco.cc/drugs/neladalkib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://www.onclive.com/view/fda-grants-priority-review-to-neladalkib-for-tki-pretreated-alk-nsclc> ;
  onco:status "phase-3" ;
  onco:modality "Small-molecule kinase inhibitor (ALK)" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/alk-positive-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/> ;
  onco:drugs <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/alectinib/> ;
  onco:companies <https://onco.cc/companies/nuvalent/> ;
  onco:trials <https://onco.cc/trials/alkove-1/>, <https://onco.cc/trials/nct06765109/> .